Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BionimeTPE:4737 -0.52%65 EV-to-EBITDA is -49.20 as of Aug. 22, 2026. GuruFocus rates TPE:4737 with a GF Score™ of 65/100 and a GF Value™ of NT$54.03 (Fairly Valued). The stock has 7 warning signs investors should review. Among 516 Medical Devices & Instruments companies, Bionime ranks worse than 193798.26% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bionime's enterprise value is NT$6,627 Mil.
Bionime's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-135 Mil. Therefore, Bionime's EV-to-EBITDA for today is -49.20.
The historical rank and industry rank for Bionime's EV-to-EBITDA or its related term are showing as below:
TPE:4737'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3148.44 Med: 22.58 Max: 118.17
Current: -49.21
During the past 13 years, the highest EV-to-EBITDA of Bionime was 118.17. The lowest was -3148.44. And the median was 22.58.
TPE:4737's EV-to-EBITDA is ranked worse than 100% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.7
vs TPE:4737: -49.21
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-08-22), Bionime's stock price is NT$57.00.
Bionime's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-4.028. Therefore, Bionime's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bionime's share price for today is NT$57.00.
Bionime's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-4.028.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Bionime's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4737 vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Bionime's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionime EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionime's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bionime's EV-to-EBITDA falls into.
Bionime's current Enterprise Value is NT$6,627 Mil.
Bionime's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-135 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionime (TPE:4737) has a EV-to-EBITDA of -49.20 as of Aug. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bionime. According to the industry distribution chart, Bionime ranks #999999 out of 516 companies in the Medical Devices & Instruments industry.
Is Bionime's EV-to-EBITDA too high?
Bionime's current EV-to-EBITDA is -49.20. Based on the distribution chart, Bionime ranks #999999 out of 516 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bionime has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bionime's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bionime ranks #999999 out of 516 companies for EV-to-EBITDA. This places Bionime in the lower half of its industry. The industry median EV-to-EBITDA is 14.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.70, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bionime. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionime's current EV-to-EBITDA is -49.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionime stock overvalued right now?
Based on GuruFocus' analysis, Bionime (TPE:4737) is currently considered Fairly Valued. The stock's GF Value™ is NT$54.03, compared to a current price of NT$57.00 — trading 5.5% above its estimated fair value. The current EV-to-EBITDA is -49.20. Bionime's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bionime (TPE:4737), the current EV-to-EBITDA is -49.20 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionime (TPE:4737) Overvalued in 2026?
Based on GuruFocus' analysis, Bionime stock appears to be overvalued.
The current stock price of NT$57.00 is trading 5.5% above its estimated GF Value™ of NT$54.03.
GuruFocus considers Bionime to be Fairly Valued.
Key valuation signals for TPE:4737:
EV-to-EBITDA: -49.20
GF Value™: NT$54.03 vs. price of NT$57.00 (5.5% above fair value)
No single metric tells the full story. See the TPE:4737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionime Corp is engaged in the manufacturing and selling of medical instruments, providing biotechnology services, examining pharmaceuticals, and selling precision instruments. The company's revenue is derived from the sale of blood glucose meters and test strips to domestic and foreign clients. Geographically, it operates in Algeria, China, Switzerland, the United States, Belarus, Egypt, the United Arab Emirates, and other countries, of which it derives the maximum revenue from Algeria.
65GF Score
Get the complete analysis for TPE:4737
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4737 has been successfully added to your 
